Puma Biotech Rebranding — Alex Maurer Designs
Takeda farms out cancer drug alisertib to Puma Biotech -
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ https://t.co/LR02TGd4oT" / Twitter
Puma Biotechnology falls more than 20%
Puma Biotechnology Inc
La EMA recomienda no aprobar el fármaco de Puma Biotech
PUMA BIOTECHNOLOGY, INC. : Precio Acción Bourse | PBYI | US74587V1070 | MarketScreener
Why Puma Biotechnology Is Soaring Today | The Motley Fool
Quartal Beschreibend Perlen puma biotech press release Region Kapitalismus Essen
Puma Biotechnology Surging
Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Here's Why The Puma Biotechnology Inc (NYSE:PBYI) Pullback Might Be A Buy-In Opportunity - Market Exclusive
Resumen: Puma Biotechnology y Pierre Fabre firman acuerdo de licencia exclusiva para desarrollar y comercializar NERLYNX® (neratinib) en Europa | Business Wire
